STOCK TITAN

Syneos Health Inc - SYNH STOCK NEWS

Welcome to our dedicated news page for Syneos Health (Ticker: SYNH), a resource for investors and traders seeking the latest updates and insights on Syneos Health.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Syneos Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Syneos Health's position in the market.

Rhea-AI Summary
FivepHusion collaborates with Treehill Partners and Syneos Health to develop and bring a novel chemotherapeutic product to market
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.84%
Tags
earnings
-
Rhea-AI Summary
Syneos Health, a biopharmaceutical solutions organization, has entered into a definitive agreement to be acquired by a consortium of private investment firms for $7.1 billion. Shareholders will receive $43.00 per share in cash, representing a 24% premium to the unaffected closing stock price. The transaction is expected to be completed in the second half of 2023, subject to shareholder and regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.84%
Tags
acquisition
-
Rhea-AI Summary
Syneos Health announces the appointment of Michael Bonello as Chief Financial Officer, effective July 1, 2023. Bonello brings over 30 years of financial leadership experience, including 15 years in the clinical research industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.5%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
earnings
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
none
Syneos Health Inc

Nasdaq:SYNH

SYNH Rankings

SYNH Stock Data

4.46B
103.27M
0.49%
94.75%
6.52%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Morrisville

About SYNH

inc research/inventiv health has become syneos health, the only fully integrated end-to-end clinical and commercial solution organization. we are purpose-built for biopharmaceutical acceleration, creating better, smarter, faster ways to help clients navigate an increasingly complex marketplace. our new business addresses today’s market realities through clinical and commercial sharing expertise and data and insights to meet the needs of emerging and large global biopharmaceutical companies.